Evolent Health, Inc Class A Common Stock
Here’s whether Evolent Health, Inc Class A Common Stock (EVH) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: 50-day MA is rising (+7.16% over 10 days); 3-month momentum positive (+34.8%). Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); RSI 28 — oversold; weak 1-year return of -54.9%; rising volume on a downtrend (distribution, 1.21x avg). Currently 59.2% off its 52-week high. Score: -3/7.
EVH is trading below its 200-day MA ($4.25) — a key warning sign the longer-term trend is under pressure. An RSI of 28.0 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -54.9% compares to +16.5% for SPY (trailed the market by 71.3%). The current 59.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.